Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: December 14, 2022
Historical Years – 2023 | Base Year – 2023 | Forecasted Years – 2024 to 2032
|
Report Attribute |
Details |
|
Market Size Value in 2023 |
US$ 50.60 million |
|
Revenue Forecast in 2032 |
US$ 68.96 million |
|
CAGR |
3.5% |
|
Base Year for Estimation |
2023 |
|
Forecast Period |
2024 to 2032 |
|
Historical Year |
2023 |
|
Segments Covered |
Hospital, Retail, and Online Pharmacies |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global epilepsy with myoclonic-atonic seizures therapeutics market was valued at US$ 50.60 million in 2023 and is expected to register a revenue CAGR of 3.5% to reach US$ 68.96 million by 2032.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Fundamentals
Epilepsy with myoclonic-atonic seizures, also known as myoclonic-atonic epilepsy or Doose syndrome, is a type of epilepsy characterized by a specific seizure type called myoclonic-atonic or atonic-myoclonic seizures. These seizures involve a sudden loss of muscle tone (atonic seizure) combined with brief muscle contractions (myoclonic jerks). This combination often leads to a sudden and involuntary collapse, resulting in falls or drops. Between the ages of 7 months and 6 years (peaking between 2 and 4 years), myoclonic-atonic epilepsy develops. Around 85% of the afflicted children had normal development before the beginning of seizures; the remaining 15% had mild psychomotor abnormalities, mostly impacting speech. The most improbable onset times are before six months or beyond six years. They often last for a long period, happen frequently, and most do so during the day. Therapeutics for epilepsy with myoclonic-atonic seizures typically involve the use of antiepileptic medications to control and manage seizures. The goal of treatment is to reduce the frequency and severity of seizures, improve the individual's quality of life, and prevent long-term complications. The specific choice of medication may vary depending on the individual's overall health, age, and any underlying conditions.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Dynamics
The prevalence of epilepsy, including myoclonic-atonic seizures, is on the rise. As awareness about epilepsy grows, there is an increased recognition of various seizure types, leading to higher diagnosis rates and a greater demand for therapeutic interventions. Ongoing research efforts to better understand the underlying causes of epilepsy, including myoclonic-atonic seizures, can lead to the development of more targeted and effective therapeutics. Advancements in neuroscience and genetics contribute to discovering new drug targets and treatment approaches. Pharmaceutical companies continue to invest in developing new AEDs with improved safety, tolerability, and efficacy profiles. The introduction of novel drugs provides healthcare professionals with additional options for managing myoclonic-atonic seizures. Advancements in technology, such as neuroimaging techniques, wearable devices, and diagnostic tools, contribute to more accurate and early diagnosis. Innovative treatment modalities, such as responsive neurostimulation or targeted drug delivery systems, may also emerge, offering new therapeutic options. Collaborations between pharmaceutical companies, academic institutions, and research organizations can accelerate drug development. Shared resources, expertise, and data can lead to more robust clinical trials and the quicker translation of research findings into practical therapeutics. Supportive regulatory frameworks that facilitate the efficient review and approval of new medications for epilepsy can encourage pharmaceutical companies to invest in research and development. Expedited pathways for breakthrough therapies can accelerate the availability of novel treatments.
However, despite advancements in epilepsy therapeutics, there may still be limited treatment options specifically tailored for myoclonic-atonic seizures. The lack of targeted medications could pose a challenge in effectively managing this specific seizure type. Many antiepileptic drugs (AEDs) can have side effects, and individuals with epilepsy may experience challenges related to the tolerability of these medications. This can lead to issues with adherence to treatment plans and impact the overall quality of life for patients, thus cramping the market growth. The cost of antiepileptic medications and other associated treatments can be a barrier for some patients, particularly if they require long-term therapy. Economic factors and healthcare accessibility can influence the ability of individuals to afford and access necessary treatments, which also restricts market growth.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Ecosystem
The global epilepsy with myoclonic-atonic seizures therapeutics market is analyzed from three perspectives: drug, distribution channel, and region.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Drug
Based on the Drug, the global epilepsy with myoclonic-atonic seizures therapeutics market is segmented into levetiracetam, sodium valproate, topiramate, and others.
The levetiracetam segment had a significant share of epilepsy, with the myoclonic-atonic seizures therapeutics market accounting for a 40% revenue share in 2023. Levetiracetam is known for its broad-spectrum antiepileptic activity, making it effective against various types of seizures. This versatility makes it a favorable choice for treating different seizure types, including myoclonic-atonic seizures. Studies and clinical trials have demonstrated the efficacy of levetiracetam in managing epilepsy. Its effectiveness in controlling seizures, including myoclonic-atonic seizures, contributes to market growth. Levetiracetam is generally well-tolerated, and it has a favorable side effect profile compared to some other antiepileptic drugs. The drug's tolerability may lead to better patient adherence and satisfaction. Levetiracetam can be used as monotherapy or adjunctive therapy, providing flexibility in its application. This makes it suitable for a wide range of patients and different stages of epilepsy management, contributing to its market prominence. Levetiracetam is approved for use in pediatric populations, making it a suitable option for children with epilepsy, including those experiencing myoclonic-atonic seizures. The availability of pediatric formulation can contribute to its dominance in this patient group. Inclusion in clinical guidelines and recommendations by healthcare organizations can significantly influence prescribing practices. Levetiracetam is often considered a relatively safe option for pregnant individuals with epilepsy. Its use during pregnancy may be a critical factor in cases where managing seizures is crucial without compromising maternal and fetal health. The availability of generic formulations of levetiracetam may contribute to its widespread use. Generic versions often offer a more cost-effective alternative, making the drug more accessible to a larger patient population.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Distribution Channel
Based on the distribution channels, the global epilepsy with myoclonic-atonic seizures therapeutics market is segmented into hospital, retail, and online pharmacies.
The hospital pharmacies accounted for the largest revenue share, with a 53% epilepsy with myoclonic-atonic seizures therapeutics market share. Hospitals play a crucial role in providing inpatient care, and patients with epilepsy, including myoclonic-atonic seizures, may require immediate intervention during emergencies. Hospital pharmacies are well-equipped to dispense medications promptly in such cases. Some hospitals, especially those with specialized epilepsy centers or neurology departments, may serve as hubs for comprehensive epilepsy care. Patients with more complex or severe forms of epilepsy, such as myoclonic-atonic seizures, may be managed in these centers. The initiation or adjustment of antiepileptic medications often occurs in a hospital setting, especially when a patient is newly diagnosed or when there's a need for close monitoring during medication changes. Hospitals often house diagnostic services, such as EEG (electroencephalogram) monitoring, which can be crucial in the diagnosis and management of epilepsy. Medication adjustments based on monitoring results may involve hospital pharmacies. Patients experiencing myoclonic-atonic seizures or other severe seizure types may be admitted to hospitals for closer monitoring and management. Hospital pharmacies play a role in providing medications for inpatient seizure control. Hospital pharmacies may be involved in the transitional care process when patients with epilepsy, including those with myoclonic-atonic seizures, are discharged from the hospital. Ensuring a smooth transition to outpatient care includes managing medication regimens.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Region
Geographically, the global Epilepsy with myoclonic-atonic seizures therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North American region has the largest Epilepsy with myoclonic-atonic seizures therapeutics market size in terms of revenue generation, accounting for around 36.50% share of the market. The prevalence of epilepsy, including myoclonic-atonic seizures, is relatively high in North America. This high prevalence is a key driver for the region's demand for therapeutics and treatment options. Around 3.4 million Americans have epilepsy, according to the CDC (Centers for Disease Control and Prevention), and 470,000 are under 17. This number can reach 139 per 100,000 in low- and middle-income nations. North America has a well-developed and advanced healthcare infrastructure with access to specialized epilepsy centers, diagnostic facilities, and a skilled healthcare workforce. Ongoing research and development initiatives in the field of epilepsy therapeutics contribute to the introduction of new medications and treatment options. Academic institutions, pharmaceutical companies, and research organizations in North America actively participate in advancing epilepsy care. Government support through initiatives, grants, and funding programs for epilepsy research and treatment in North America can stimulate market growth. Funding from government agencies supports research, drug development, and access to care. North America is a hub for technological advancements in healthcare. Innovations in diagnostic tools, neuroimaging, and telemedicine contribute to improved epilepsy diagnosis, personalized treatment plans, and enhanced patient care. Favorable insurance coverage and reimbursement policies in North America can positively impact the accessibility of epilepsy therapeutics. Patients with adequate coverage are more likely to access and adhere to prescribed treatments.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Competitive Landscape
The prominent players operating in the global epilepsy with myoclonic-atonic seizures therapeutics market are:
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Strategic Developments
Myoclonic-atonic epilepsy (MAE) is an uncommon form of pediatric epilepsy characterized by myoclonic-atonic seizures, frequently identified by jerking muscular spasms followed by abrupt muscle limpness. Between the ages of 7 months and 6 years (peaking between 2 and 4 years), myoclonic-atonic epilepsy develops.
Asia Pacific can be considered the key growth region due to the surge in epilepsy with myoclonic-atonic seizure therapeutics industry trends in China, Japan, and the Indian subcontinent.
The prominent players operating in the global epilepsy with myoclonic-atonic seizures therapeutics market are Sanofi S.A., AbbVie Inc., Jazz Pharmaceuticals Plc, Sun Pharmaceuticals Industries Ltd., Janssen Pharmaceuticals, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Pfizer Inc., Eisai Co., Ltd., UCB Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited.
The estimated size of the global epilepsy with myoclonic-atonic seizures therapeutics market in 2032 is US$ 68.96 million.
The global epilepsy with myoclonic-atonic seizures therapeutics market growth is estimated to grow at a revenue CAGR of 3.5% during the forecast period from 2024 to 2032.
*Insights on financial performance are subject to the availability of information in the public domain
List of Tables
List of Figures